Hospital Universitario De Leon — Clinical Trial Site

84 Registered trials

34 Currently recruiting

Organisation

Hospital Universitario De Leon

Location

Leon, Spain

Identifier

ORG-100030135

Address

Calle Altos De Nava S/n, 24071, Spain

Departments

7005: Oncología Medica
Anestesiología y Reanimación
Aparato Digestivo
Cardiología
Cardiology
Cirugía general
Digestive
Digestive Department
Digestive service
Digestivo
Endocrinology and Metabolism
Hematología
Hematology
Hematology and Transfusion Medicine
medical oncologist
Medical Oncology
Neurología
Neurology
Obstetrician and Gynecologist
Oftalmología
Oncología
Oncology
Oncology Department
Planta cero, Oncologia Tratamientos, Despacho de Investigaci
Servicio de Cardiologia
Servicio de Endocrinologia
Servicio de Hematología
Servicio de Oncología Médica

Clinical trials at this site (84)

Search interface

A phase II study assessing safety and efficacy of REPotrectinib in ROS1-positive non-small cell lung cancer patients with active brain mEtas… Recruiting

2023-508112-35-00 ROS1-positive non-small cell lung cancer (NSCLC) with a 4 2025-04-15
Study of treatment with sacituzumab and zimkberelimab for patients with lung cancer confined to the chest and previously operated on who wer… Recruiting

2024-512960-75-00 Resectable Non-small cell lung cancer 5 2025-02-04
ANALYSIS OF EFFECTIVENESS OF NEOADJUVANT CHEMOTHERAPY IN THE TREATMENT OF LOCALLY ADVANCED COLON CANCER. Recruiting

2024-519825-39-00 Locally advanced colon cancer (LACC) 4 2025-01-30
A study to investigate the safety and efficacy of GSK4532990 compared with placebo in adult participants aged 18 to 65 years with alcohol-re… Recruiting

2024-511596-15-00 Liver Diseases, Alcoholic 4 2024-12-26
Treatment with a single drug that prevents blood clot formation followed by an anticoagulant drug in patients with irregular heartbeat who h… Recruiting

2023-509717-36-00 AF patients who have undergone successful PCI 5 2024-12-16
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting

2024-512279-10-00 Triple Negative Breast Cancer 5 2024-11-25
Immunotherapy and chemotherapy treatment or no treatment guided by the level of tumour-infiltrating cells in resected early-stage triple-neg… Recruiting

2023-504620-26-00 Triple negative breast cancer 4 2024-11-04
STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C… Recruiting

2023-505871-63-00 ER+, HER2- metastatic breast cancer following endocrine 5 2024-04-08
A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe… Recruiting

2023-503412-33-00 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small 5 2024-03-29
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab… Recruiting

2023-503224-66-00 Atrial Fibrillation 5 2023-10-31
A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) (COM… Recruiting

2024-516330-35-00 Non-Small Cell Lung Cancer 5 2021-09-29
Radiation-Free Therapy for the Initial treatment of Good prognosis early non-bulky HL, defined by a low Metabolic Tumor Volume and a negativ… Recruiting

2024-515063-66-00 Early stage classical Hodgkin Lymphoma (cHL) without bu 4 2021-03-30
LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES Recruiting

2022-502706-33-00 Patients with invasive breast cancer in early stages 6 2018-01-10
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended

2025-521067-13-00 Atherosclerotic Cardiovascular Disease (ASCVD) 5 2026-04-24
Ribociclib in combination with endocrine therapy in patients with “estrogen receptor-positive and HER2-negative” breast cancer with high ris… Ended

2023-508827-10-00 Patients with primary operable stage II, grade 2 or 3, 4 2025-10-13
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening);… Ended

2024-519000-27-00 Hypertension 5 2025-07-17
A Multicenter, Open-Label, Single-Arm, Phase II Trial Exploring the Maintenance of Trastuzumab and Pertuzumab Following Trastuzumab Deruxtec… Ended

2023-507306-13-00 HER2-positive unresectable locally recurrent or metasta 4 2025-04-13
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women with Breast Cancer Who Are Having Hormone Therapy Ended

2024-510719-31-00 Moderate to Severe Vasomotor Symptoms (VMS) 5 2025-01-24
A phase II, open-label, multicenter study of orally administered RVU120 for the treatment of anemia in patients with lower-risk myelodysplas… Ended

2023-509947-29-00 Anemia in patients with very low, low or intermediate r 4 2024-07-18
A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu… Ended

2022-502781-24-01 ASCVD - Atherosclerotic Cardiovascular Disease 5 2024-06-05
A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Par… Ended

2022-501396-62-00 Relapsed Refractory Multiple Myeloma 5 2023-12-12
An open label, multicenter, phase II study of Elranatamab as single agent for the treatment of relapsed or refractory myeloma in patients pr… Ended

2023-504273-21-00 Multiple Myeloma 4 2023-10-31
Study to evaluate reduced antiplatelet therapy after angiolite stent implantation in patients with coronary artery disease Ended

2023-507015-35-00 Coronary Artery Disease 5 2023-10-06